Olatz Arteaga-Cabeza

Dr. Olatz Arteaga-Cabeza


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
OAOlatz Arteaga-Cabeza
Olatz Arteaga-Cabeza
AÁAntonia Álvarez
Antonia Álvarez
MRMiren Revuelta
Miren Revuelta
FSFrancisco Santaolalla
Francisco Santaolalla
AUAndoni Urtasun
Andoni Urtasun
EHEnrique Hilario
Enrique Hilario
Hypoxic–ischemic brain damage is an alarming health and economic problem in spite of the advances in neonatal care. It can cause mortality or detrimental neurological disorders such as cerebral palsy, motor impairment and cognitive deficits in neonates. When hypoxia–ischemia occurs, a multi-faceted cascade of events starts out, which can eventually cause cell death. Lower levels of oxygen due to reduced blood supply increase the production of reactive oxygen species, which leads to oxidative stress, a higher concentration of free cytosolic calcium and impaired mitochondrial function, triggering the activation of apoptotic pathways, DNA fragmentation and cell death. The high incidence of this type of lesion in newborns can be partly attributed to the fact that the developing brain is particularly vulnerable to oxidative stress. Since antioxidants can safely interact with free radicals and terminate that chain reaction before vital molecules are damaged, exogenous antioxidant therapy may have the potential to diminish cellular damage caused by hypoxia–ischemia. In this review, we focus on the neuroprotective effects of antioxidant treatments against perinatal hypoxic–ischemic brain injury, in the light of the most recent advances.

6 November 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OAOlatz Arteaga-Cabeza
Olatz Arteaga-Cabeza
MRMiren Revuelta
Miren Revuelta
LULeyre Urigüen
Leyre Urigüen
AÁAntonia Álvarez
Antonia Álvarez
HMHaizea Montalvo
Haizea Montalvo
EHEnrique Hilario
Enrique Hilario
Despite advances in neonatal care, hypoxic-ischemic brain injury is still a serious clinical problem, which is responsible for many cases of perinatal mortality, cerebral palsy, motor impairment and cognitive deficits. Resveratrol, a natural polyphenol with important anti-oxidant and anti-inflammatory properties, is present in grapevines, peanuts and pomegranates. The aim of the present work was to evaluate the possible neuroprotective effect of resveratrol when administered before or immediately after a hypoxic-ischemic brain event in neonatal rats by analyzing brain damage, the mitochondrial status and long-term cognitive impairment. Our results indicate that pretreatment with resveratrol protects against brain damage, reducing infarct volume, preserving myelination and minimizing the astroglial reactive response. Moreover its neuroprotective effect was found to be long lasting, as behavioral outcomes were significantly improved at adulthood. We speculate that one of the mechanisms for this neuroprotection may be related to the maintenance of the mitochondrial inner membrane integrity and potential, and to the reduction of reactive oxygen species. Curiously, none of these protective features was observed when resveratrol was administered immediately after hypoxia-ischemia.

29 October 2016 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
OAOlatz Arteaga-Cabeza
Olatz Arteaga-Cabeza
MRM. Revuelta
M. Revuelta
LUL. Urigüen
L. Urigüen
LML. Martínez-Millán
L. Martínez-Millán
EHE. Hilario
E. Hilario
AÁA. Álvarez
A. Álvarez

Verified
Journal Article
Open access
PDF file
JRJuanma Ramirez
Juanma Ramirez
GPGorka Prieto
Gorka Prieto
EBErik P. Barrio
Erik P. Barrio
AAAinhoa Atxa-Espiga
Ainhoa Atxa-Espiga
NPNatalia Presa
Natalia Presa
NONerea Osinalde
Nerea Osinalde
Deubiquitinases (DUBs) of the ubiquitin C-terminal hydrolase (UCH) family play critical roles in regulating ubiquitin-dependent signaling, yet their substrate specificity and functional organization remain incompletely defined. Here, we systematically characterized the ubiquitination landscape associated with UCH family members (UCHL1, UCHL3, UCHL5, and BAP1) using a quantitative proteomics workflow combining siRNA-mediated DUB silencing, bioUb-based enrichment of ubiquitinated proteins, and label-free mass spectrometry. Proteins exhibiting increased ubiquitination following DUB depletion were identified as candidate substrates. Our analysis revealed that UCH family members regulate largely distinct subsets of ubiquitinated proteins, with limited overlap in their candidate profiles despite sharing conserved catalytic domains. In parallel, site-resolved ubiquitinomics identified 851 ubiquitination sites, including 106 not previously reported, expanding the current landscape of experimentally validated ubiquitin-modified lysines. Functionally, substrate networks link individual UCH enzymes to distinct yet partially overlapping cellular processes, including hypoxia signaling, RNA metabolism, vesicle trafficking, apoptosis, and chromatin regulation. Notably, known substrates such as HIF-1α validated the approach, while recurrent detection of key regulators, including MCL1, pointed to convergence at the level of apoptosis control. Together, these findings provide a resource for exploring the distinct and potentially overlapping roles of UCH deubiquitinases within cellular ubiquitin-regulatory networks.